Login to Your Account



Up To $53.5M Due Later

InterMune Buys Back Rights To Pirfenidone: $13.5M Cash

By Randall Osborne


Tuesday, November 27, 2007
With its hepatitis C virus protease inhibitor in Phase Ib trials, InterMune Inc.'s buyout of rights to pirfenidone for $13.5 million up front and as much as $53.5 million later puts the firm in position for another run against idiopathic pulmonary fibrosis (IPF) - the lung-scarring condition against which Actimmune failed earlier this year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription